Source disclosure: February 16, 2026
Kidswell Bio Corporation [4584.T]
TOKYO, Feb 16 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) agreed to establish a joint venture subsidiary in the U.S. with British firm Treehill Partners to accelerate clinical development of stem cell therapies derived from children's baby teeth.
The new entity, tentatively named Kidswell USA, will focus on treating cerebral palsy, targeting a condition affecting approximately one in 345 children annually in the U.S., according to National Institutes of Health estimates. Under the agreement, Kidswell Bio will contribute its proprietary stem cell technology and manufacturing expertise, while Treehill Partners will leverage its experience and specialized knowledge in clinical development optimization. The partnership also includes collaboration with leading biotech firm Thermo Fisher Scientific for development support.
"We aim to efficiently advance our innovative cell therapy pipeline in the U.S. market," said Shinya Akayama, President and CEO of Kidswell Bio. "This strategic alliance combines our strengths to address unmet medical needs and bring new treatments to patients." Ali Pashazadeh, CEO and founder of Treehill Partners, emphasized the importance of optimizing development processes to ensure successful clinical outcomes and expedite patient access to novel therapies.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing